Nilotinib Zentiva

Nilotinib, the active ingredient in Nilotinib Zentiva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia in adult patients, targeting the BCR‑ABL fusion protein that drives disease progression.

GNH USA supplies Nilotinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution. Our network ensures reliable delivery to clinical sites in Europe, Asia, Africa and the Americas.

Nilotinib is used to target BCR‑ABL–positive leukemias, primarily chronic myeloid leukemia. - Chronic phase CML: reduces leukemic cell proliferation and achieves cytogenetic and molecular responses. - Accelerated phase CML: helps achieve disease control and prolongs survival. - Blast phase CML: used as part of combination therapy to attain remission.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Rash or skin irritation - Nausea or vomiting - Diarrhea - Elevated liver enzymes - Fatigue or weakness - Muscle cramps or joint pain

Serious or Rare Side Effects: - Cardiovascular events such as arterial occlusion - Severe pancreatitis - Hepatic failure - QT interval prolongation leading to arrhythmia - Severe infections - Pulmonary arterial hypertension

When prescribing nilotinib, clinicians should consider several precautionary measures to minimize risk. - Cardiac assessment: evaluate baseline ECG and cardiovascular risk factors before initiating therapy. - Hepatic monitoring: check liver function tests regularly during treatment. - Electrolyte balance: monitor serum potassium and magnesium to reduce QT prolongation risk. - Drug interactions: avoid concomitant use of strong CYP3A4 inhibitors or inducers without adjustment. - Pregnancy and lactation: contraindicated in pregnancy; advise effective contraception and avoid breastfeeding. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Nilotinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nilotinib levels and risk serious adverse events. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can markedly reduce efficacy by lowering drug exposure. - Antacids containing aluminum or magnesium: interfere with absorption; should be avoided or spaced apart.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, H2 blockers): may decrease absorption; monitor therapeutic response. - QT‑prolonging drugs (e.g., fluoroquinolones, certain antiarrhythmics): increase risk of cardiac arrhythmias; ECG monitoring recommended. - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): may require dose adjustment to avoid muscle toxicity.